Covista Inc. (CVSA) Fair Value & Analysis
Consumer Defensive · US · Market cap $4.0B · ISIN US00737L1035
What is Covista Inc. really worth?
Covista Inc.
CVSA · US
A strong business, currently priced close to our fair value of $135.45.
Strengths
Risks
Fair value as of: Aug 13, 2026
From 26 valuation models · updated 22 days ago
Share price −1.7% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- A fairly wide model range ($86.16 to $173.53) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range $19.74 – $154.45 · fair‑value band $86.16 – $173.53 · the $127.64 price screens below the $135.45 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Covista Inc. (CVSA) currently trades at $127.64, while our model-based Fair Value estimate is $135.45, implying the stock looks roughly 5.8% fairly valued today. The Quality Score stands at 80/100 (high quality), in the Consumer Defensive sector. Bull case: the Growth Earnings group reads highest at a median of $128.45 per share, and 9 of the 26 models we run sit above the $127.64 price. Bear case: the Asset-Based group reads lowest at $28.23, and 17 of the 26 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Covista Inc. generated revenue of $1.9B at a net margin of 12.3%. Revenue grew 4.5% year over year. It earns a return on equity of 17.9%. Net debt stands at $574M. Fundamentals as of Aug 13, 2026
Our scenario range runs from $86.16 (bear case) to $173.53 (bull case); at $127.64, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 18% below its 52-week high and 47% above its 52-week low, currently above its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at 8% fair-value upside, at 6%, CVSA screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 12 months have passed since. In that time the company retained roughly $6.87 per share, which is 5.1 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 26 models by family
Widest divergence: Growth Earnings ($128.45) versus Dividend Discount ($1.30). Highest evidence: FCF DCF (80).
Notify me when CVSA reaches fair value
Put CVSA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 74 · Market factors (momentum, volatility) 48
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Covista Inc., together with its subsidiaries, provides healthcare education in the United States, Barbados, St. Kitts, and St. Maarten. It operates in three segments: Chamberlain, Walden, and Medical and Veterinary.
Full company description
Covista Inc., together with its subsidiaries, provides healthcare education in the United States, Barbados, St. Kitts, and St. Maarten. It operates in three segments: Chamberlain, Walden, and Medical and Veterinary. The company offers degree and non-degree programs, including bachelor's, master's, and doctoral degrees; and online certificate programs for nursing, health professions, medical, and veterinary postsecondary education, counseling, business, information technology, psychology, public health, social work and human services, public administration and public policy, and criminal justice. It also operates Chamberlain University, Walden University, American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine. The company was formerly known as Adtalem Global Education Inc. and changed its name to Covista Inc. in February 2026. Covista Inc. was incorporated in 1987 and is headquartered in Chicago, Illinois.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Covista Inc. reported revenue of $1.8B in FY2025 versus $907M in FY2021, a compound +18.5%/yr. Reported net income was $233M in FY2025, compounding +31.9%/yr from FY2021.
of which total revenue −1.8 % · buybacks/dilution +4.9 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
Watch CVSA: get an alert when its fair value changes →
Earlier news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Consumer Discretionary - Education Services Stocks Q2 Teardown: Covista (NYSE:CVSA) Vs The Rest
- Covista (CVSA) Stock Trades Up, Here Is Why
- Covista Q4 Earnings & Revenues Top Estimates, Enrollments Up Y/Y
- Covista Inc (CVSA) (Q4 2026) Earnings Call Highlights: Record Enrollment and Strong Cash Flow ...
Peer Group
Education & Training Services · 142 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Education & Training Services median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 66/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Education & Training Services stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| New Oriental Education & Technology Group EDU | $58.22 | $48.37 | −17% |
| TAL Education Group TAL | $11.69 | $15.60 | +33% |
| Laureate Education, Inc LAUR | $38.36 | $41.45 | +8% |
| Physicswallah Limited PWL | ₹119.46 | ₹13.69 | −89% |
| Grand Canyon Education, Inc LOPE | $151.19 | $152.01 | +1% |
| Stride, Inc LRN | $84.58 | $139.45 | +65% |
| Universal Technical Institute, Inc UTI | $25.64 | $20.98 | −18% |
| Perdoceo Education Corporation PRDO | $33.81 | $40.65 | +20% |
| Strategic Education, Inc STRA | $81.90 | $105.48 | +29% |
| Offcn Education Technology Co 002607 | ¥2.03 | ¥0.3300 | −84% |
Compare Covista Inc. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Covista Inc. (CVSA) overvalued or undervalued?
What is the fair value of CVSA?
What is the quality score of CVSA?
What is the revenue of Covista Inc. (CVSA)?
What is the net profit margin of CVSA?
Does Covista Inc. pay a dividend?
Watch Covista Inc. in the live analysis
One click puts Covista Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.